Module
Hepatitis Journal Options – Volume 3, Issue 3
Source: Journal Options
Hepatitis Journal Options – Volume 3, Issue 3
Program Directors: Raymond T. Chung, MD, Robert G. Gish, MD, Stephen A. Harrison, MD, LTC, MC
  
- Natalie H. Bzowej, MD, PhD
- Peter Ferenci, MD
- Michael Gale, Jr., PhD
|
  
- Stuart C. Gordon, MD
- Tarek Hassanein, MD, FACP, FACG, AGAF
- Paul Y. Kwo, MD
|
 
- Alessandra Mangia, MD
- Sammy Saab, MD, MPH, AGAF
|
|
Learning Objectives
Upon completion of this activity, participants should be able to:
- Recall data on biochemical markers that predict disease progression rates and response rates to peginterferon in HBV-infected patients
- Discuss the efficacy of lactulose for preventing hepatic encephalopathy recurrence in patients with cirrhosis
- Discuss the ability of total cholesterol, genetic markers, and oxidative stress biomarkers to predict successful HCV treatment with peginterferon/ribavirin
- Describe response rates with peginterferon alfa-2a vs peginterferon alfa-2b and standard vs individualized treatment durations in HCV-infected persons
- Summarize how weight-related factors affect the progression of liver disease in HCV-infected persons
|
Disclaimer:
The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.
|
Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC.
Contact Info
Educational grants provided by:
Educational grants support only the CME-certified components of this program.
|
|